{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:31:35Z","timestamp":1789507895055,"version":"build-2803163510"},"reference-count":162,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["SUBZ.C200.26.031"],"award-info":[{"award-number":["SUBZ.C200.26.031"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Ribosomes are central to cellular growth and proteome maintenance, and cancer cells frequently depend on increased ribosome biogenesis and altered translation to sustain proliferation, stress tolerance, and metabolic rewiring. Paradoxically, inherited \u201cribosomopathies\u201d caused by germline defects in ribosomal proteins or ribosome biogenesis factors present with tissue hypoplasia and bone marrow failure early in life, yet confer substantially increased lifetime risk of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and selected solid tumors. In parallel, somatic alterations affecting ribosomal proteins and ribosome regulatory pathways recur across malignancies, including hematologic cancers such as T-cell acute lymphoblastic leukemia (T-ALL), and in pediatric solid tumors. Mechanistically, oncogenic ribosome disturbances can reprogram translation toward specific mRNA subsets, alter translational fidelity, trigger nucleolar\/ribosomal stress signaling via the 5S ribonucleoprotein (5S RNP)\u2013MDM2\u2013p53 axis, and enable selection for compensatory or cooperating lesions (notably TP53 pathway alterations). Clinically, these insights support diagnostics and surveillance of inherited ribosome-related cancer predisposition syndromes, therapeutic targeting of ribosome biogenesis and translational control, including RNA polymerase I inhibition, and the eIF4 translation-initiation machinery. Here, we present current evidence linking constitutional and acquired ribosomal dysfunction to leukemogenesis and tumorigenesis, highlight disease- and context-specific mechanisms, and outline priorities for translational research and precision therapy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1832877","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:30:44Z","timestamp":1781843444000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis"],"prefix":"10.3389","volume":"16","author":[{"given":"Michalina","family":"Horochowska","sequence":"first","affiliation":[{"name":"Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Jakubczyk","sequence":"additional","affiliation":[{"name":"Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, University Clinical Hospital","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ussowicz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4087","article-title":"Ribosome biogenesis: A central player in cancer metastasis and therapeutic resistance","volume":"82","author":"Elhamamsy","year":"2022","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2819","article-title":"MYC as a regulator of ribosome biogenesis and protein synthesis","volume":"10","author":"van Riggelen","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","article-title":"Ribosome biogenesis in cancer: New players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-4525-4_10","article-title":"Basic mechanisms in RNA polymerase I transcription of the ribosomal RNA genes","author":"Goodfellow","year":"2013","journal-title":"Epigenetics: Development and Disease"},{"key":"B5","doi-asserted-by":"publisher","first-page":"a018408","DOI":"10.1101\/cshperspect.a018408","article-title":"MYC regulation of cell growth through control of transcription by RNA polymerases I and III","volume":"4","author":"Campbell","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909873106","article-title":"AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply","volume":"106","author":"Hoppe","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.celrep.2013.05.045","article-title":"5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint","volume":"4","author":"Donati","year":"2013","journal-title":"Cell Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molcel.2013.02.001","article-title":"Splicing-factor oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence","volume":"50","author":"Fregoso","year":"2013","journal-title":"Mol Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.128","article-title":"Disruption of the 5S RNP\u2013Mdm2 interaction significantly improves the erythroid defect in a mouse model for Diamond-Blackfan anemia","volume":"29","author":"Jaako","year":"2015","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.15252\/emmm.201606660","article-title":"Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with <scp>TP<\/scp> 53 mutations","volume":"9","author":"Ajore","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.07.018","article-title":"The discovery of ribosome heterogeneity and its implications for gene regulation and organismal life","volume":"71","author":"Genuth","year":"2018","journal-title":"Mol Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3359","article-title":"Specialized ribosomes: A new frontier in gene regulation and organismal biology","volume":"13","author":"Xue","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2023.0387","article-title":"Ribosomal protein paralogues in ribosome specialization","volume":"380","author":"Milenkovic","year":"2025","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1038\/s41467-022-33263-3","article-title":"A stem cell roadmap of ribosome heterogeneity reveals a function for RPL10A in mesoderm production","volume":"13","author":"Genuth","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0176-z","article-title":"The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL","volume":"33","author":"Kampen","year":"2019","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.1.280-288.2003","article-title":"The internal ribosome entry site-mediated translation of antiapoptotic protein XIAP is modulated by the heterogeneous nuclear ribonucleoproteins C1 and C2","volume":"23","author":"Hol\u010d\u00edk","year":"2003","journal-title":"Mol Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1123835","article-title":"Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita","volume":"312","author":"Yoon","year":"2006","journal-title":"Sci (1979)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707674114","article-title":"Evidence for rRNA 2\u2032-O-methylation plasticity: Control of intrinsic translational capabilities of human ribosomes","volume":"114","author":"Erales","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.08.013","article-title":"P53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer","volume":"24","author":"Marcel","year":"2013","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.celrep.2019.07.046","article-title":"Ribosome collisions result in +1 frameshifting in the absence of no-go decay","volume":"28","author":"Simms","year":"2019","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402670111","article-title":"Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3\u2032 UTR","volume":"111","author":"Goodenough","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03054-1","article-title":"Anti-tumour immunity induces aberrant peptide presentation in melanoma","volume":"590","author":"Bartok","year":"2021","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/s41467-026-68979-z","article-title":"Protein C-terminal variations impact proteostasis","volume":"17","author":"Chu","year":"2026","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0550","article-title":"How ribosomes translate cancer","volume":"7","author":"Sulima","year":"2017","journal-title":"Cancer Discov"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006894","article-title":"The T-cell leukemia related rpl10-R98S mutant traps the 60S export adapter Nmd3 in the ribosomal P site in yeast","volume":"13","author":"Patchett","year":"2017","journal-title":"PloS Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.225","article-title":"The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling","volume":"32","author":"Girardi","year":"2018","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","article-title":"Ribosomal proteins and human diseases: Molecular mechanisms and targeted therapy","volume":"6","author":"Kang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.03.052","article-title":"Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer","volume":"157","author":"Cunningham","year":"2014","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205153","article-title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin","volume":"114","author":"Assouline","year":"2009","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/wrna.117","article-title":"The box C\/D and H\/ACA snoRNPs: Key players in the modification, processing and the dynamic folding of ribosomal RNA","volume":"3","author":"Watkins","year":"2012","journal-title":"WIREs RNA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00718-3","article-title":"Small nucleolar RNAs","volume":"109","author":"Kiss","year":"2002","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1269","article-title":"An overview of pre-ribosomal RNA processing in eukaryotes","volume":"6","author":"Henras","year":"2015","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2016.1259781","article-title":"Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function","volume":"14","author":"Sloan","year":"2017","journal-title":"RNA Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.07.008","article-title":"\u2018View from a bridge\u2019: A new perspective on eukaryotic rRNA base modification","volume":"40","author":"Sharma","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13402-012-0113-5","article-title":"Expression of small nucleolar RNAs in leukemic cells","volume":"36","author":"Teittinen","year":"2013","journal-title":"Cell Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.11.058","article-title":"Beyond microRNA \u2013 Novel RNAs derived from small non-coding RNA and their implication in cancer","volume":"340","author":"Martens-Uzunova","year":"2013","journal-title":"Cancer Lett"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152534","article-title":"Ribosome biogenesis and function in cancer: From mechanisms to therapy","volume":"17","author":"Gitareja","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3563","article-title":"AML1-ETO requires enhanced C\/D box snoRNA\/RNP formation to induce self-renewal and leukaemia","volume":"19","author":"Zhou","year":"2017","journal-title":"Nat Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004121","article-title":"Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation","volume":"135","author":"Pauli","year":"2020","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0210","article-title":"A dynamic rRNA ribomethylome drives stemness in acute myeloid leukemia","volume":"13","author":"Zhou","year":"2023","journal-title":"Cancer Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/112608","article-title":"Analysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot study","volume":"29","author":"Ussowicz","year":"2020","journal-title":"Adv Clin Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cimb48010074","article-title":"Altered expression of ribosome biogenesis regulators (TP53, C-MYC, FBL, and NCL) in precursor B-cell acute lymphoblastic leukemia and neuroblastoma","volume":"48","author":"Horochowska","year":"2026","journal-title":"Curr Issues Mol Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.3.931","article-title":"cDNA cloning and sequencing of human fibrillarin, a conserved nucleolar protein recognized by autoimmune antisera","volume":"88","author":"Aris","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature12819","article-title":"Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification","volume":"505","author":"Tessarz","year":"2014","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-024-01420-z","article-title":"Phase separation-competent FBL promotes early pre-rRNA processing and translation in acute myeloid leukaemia","volume":"26","author":"Yang","year":"2024","journal-title":"Nat Cell Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1218535109","article-title":"Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress","volume":"109","author":"Bursa\u0107","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.189","article-title":"Ribosome biogenesis surveillance: Probing the ribosomal protein-Mdm2-p53 pathway","volume":"29","author":"Deisenroth","year":"2010","journal-title":"Oncogene"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256230","article-title":"FBL promotes cancer cell resistance to DNA damage and BRCA1 transcription via YBX1","volume":"24","author":"Sun","year":"2023","journal-title":"EMBO Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.biochi.2025.07.018","article-title":"Ribosome biogenesis is a therapeutic vulnerability in pediatric neuroblastoma","volume":"238","author":"Jouines","year":"2025","journal-title":"Biochimie"},{"key":"B51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12887-020-02219-1","article-title":"Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Pediatr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.17.12.7088","article-title":"Nucleolar KKE\/D repeat proteins Nop56P and Nop58P interact with Nop1p and are required for ribosome biogenesis","volume":"17","author":"Gautier","year":"1997","journal-title":"Mol Cell Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1017\/S1355838200992446","article-title":"Box C\/D snoRNA-associated proteins: Two pairs of evolutionarily ancient proteins and possible links to replication and transcription","volume":"6","author":"Newman","year":"2000","journal-title":"RNA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03483.x","article-title":"RNA\u2010modifying machines in archaea","volume":"48","author":"Omer","year":"2003","journal-title":"Mol Microbiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2016.1243646","article-title":"Assembly and trafficking of box C\/D and H\/ACA snoRNPs","volume":"14","author":"Massenet","year":"2017","journal-title":"RNA Biol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.molcel.2018.08.017","article-title":"Box C\/D snoRNP autoregulation by a cis-acting snoRNA in the NOP56 pre-mRNA","volume":"72","author":"Lykke-Andersen","year":"2018","journal-title":"Mol Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1295422","article-title":"NOP58 induction potentiates chemoresistance of colorectal cancer cells through aerobic glycolysis as evidenced by proteomics analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0831","article-title":"Deletion 6q drives T-cell leukemia progression by ribosome modulation","volume":"8","author":"Gachet","year":"2018","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2508","article-title":"Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia","volume":"45","author":"De Keersmaecker","year":"2013","journal-title":"Nat Genet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3452","article-title":"The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer","volume":"48","author":"Siprashvili","year":"2016","journal-title":"Nat Genet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1224","article-title":"c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I","volume":"7","author":"Grandori","year":"2005","journal-title":"Nat Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1455","article-title":"First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: Results of a phase I dose-escalation study","volume":"9","author":"Khot","year":"2019","journal-title":"Cancer Discov"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403722200","article-title":"Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5","volume":"279","author":"Dai","year":"2004","journal-title":"J Biol Chem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"a014241","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026245","article-title":"Targeting the MDM2\u2013p53 protein\u2013protein interaction for new cancer therapy: Progress and challenges","volume":"7","author":"Wang","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.158","article-title":"The dual PI3 kinase\/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML","volume":"22","author":"Kojima","year":"2008","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.112.6.761","article-title":"Structure and functions of nucleolin","volume":"112","author":"Ginisty","year":"1999","journal-title":"J Cell Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11033-025-10758-y","article-title":"The multifaceted roles of nucleolin in viral entry, replication, and antiviral therapy","volume":"52","author":"Pandey","year":"2025","journal-title":"Mol Biol Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149479","article-title":"Investigating the multifaceted role of nucleolin in cellular function and cancer: Structure, regulation, and therapeutic implications","volume":"957","author":"Prakash","year":"2025","journal-title":"Gene"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.13.14.1911","article-title":"Molecular dissection of nucleolin\u2019s role in growth and cell proliferation: new insights","volume":"13","author":"Srivastava","year":"1999","journal-title":"FASEB J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200304132","article-title":"Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels","volume":"163","author":"Christian","year":"2003","journal-title":"J Cell Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170160","article-title":"Expression profiling of ribosome biogenesis factors reveals nucleolin as a novel potential marker to predict outcome in AML patients","volume":"12","author":"Marcel","year":"2017","journal-title":"PloS One"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-043257","article-title":"Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA","volume":"109","author":"Otake","year":"2007","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cell.2005.07.034","article-title":"Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin","volume":"123","author":"Takagi","year":"2005","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13046-021-01993-9","article-title":"Cell surface nucleolin represents a novel cellular target for neuroblastoma therapy","volume":"40","author":"Brignole","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.062189599","article-title":"A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo","volume":"99","author":"Porkka","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Invest New Drugs"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5723","article-title":"The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells","volume":"68","author":"Soundararajan","year":"2008","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-471094","article-title":"Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex","volume":"121","author":"Wise","year":"2013","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12915-015-0132-6","article-title":"snoRNAs are a novel class of biologically relevant Myc targets","volume":"13","author":"Herter","year":"2015","journal-title":"BMC Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.05804-11","article-title":"Requirement of rRNA methylation for 80S ribosome assembly on a cohort of cellular internal ribosome entry sites","volume":"31","author":"Basu","year":"2011","journal-title":"Mol Cell Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.89.Silvera","article-title":"Ribosomes: the future of targeted therapies","volume":"4","author":"Marcel","year":"2013","journal-title":"Oncotarget"},{"key":"B84","article-title":"Cell cycle control in acute myeloid leukemia","volume":"2","author":"Schnerch","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1038\/ncomms4630","article-title":"The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes","volume":"5","author":"Huether","year":"2014","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat Rev Genet"},{"key":"B87","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","article-title":"Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53","volume":"22","author":"Bywater","year":"2012","journal-title":"Cancer Cell"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375972","article-title":"Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry","volume":"119","author":"Vlachos","year":"2012","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00063-2","article-title":"Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement","volume":"11","author":"Wlodarski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2018.10.027","article-title":"The genetic landscape of Diamond-Blackfan anemia","volume":"103","author":"Ulirsch","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295238","article-title":"Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells","volume":"117","author":"Dutt","year":"2011","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-848937","article-title":"Increased risk of colon cancer and osteogenic sarcoma in Diamond-Blackfan anemia","volume":"132","author":"Vlachos","year":"2018","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024956","article-title":"Proteostasis disruption in inherited bone marrow failure syndromes","volume":"146","author":"Yu","year":"2025","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112138","article-title":"Ribosomal protein deficiencies linked to Diamond-Blackfan anemia induce distinctive alterations of ATF4 expression","volume":"28","author":"Lorenzo-Mart\u00edn","year":"2025","journal-title":"iScience"},{"key":"B95","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ng1062","article-title":"Mutations in SBDS are associated with Shwachman-Diamond syndrome","volume":"33","author":"Boocock","year":"2003","journal-title":"Nat Genet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1749-6632.2011.06349.x","article-title":"Draft consensus guidelines for diagnosis and treatment of Shwachman\u2010Diamond syndrome","volume":"1242","author":"Dror","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92876","article-title":"Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond\u2013like features","volume":"127","author":"Carapito","year":"2017","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017739","article-title":"Predisposition to myeloid Malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances","volume":"141","author":"Reilly","year":"2023","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41467-021-21588-4","article-title":"Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome","volume":"12","author":"Kennedy","year":"2021","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026507","article-title":"Lymphoid Malignancies in patients with Shwachman-Diamond syndrome","volume":"145","author":"Reed","year":"2025","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.480","article-title":"Dyskeratosis congenita","volume":"2011","author":"Dokal","year":"2011","journal-title":"Hematology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1261\/rna.078953.121","article-title":"Dyskerin: an essential pseudouridine synthase with multifaceted roles in ribosome biogenesis, splicing, and telomere maintenance","volume":"27","author":"Garus","year":"2021","journal-title":"RNA"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.04.030","article-title":"H\/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation","volume":"3","author":"Bellodi","year":"2013","journal-title":"Cell Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0903373","article-title":"Telomere diseases","volume":"361","author":"Calado","year":"2009","journal-title":"N Engl J Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19767","article-title":"Haematological features of telomere biology disorders diagnosed in adulthood: a French nationwide study of 127 patients","volume":"205","author":"Bertuch","year":"2024","journal-title":"Br J Haematol"},{"key":"B106","unstructured":"Bertuch\n              AA\n            \n            \n              Calado\n              RT\n            \n            \n              Carr\n              AG\n            \n          \n          Telomere Biology Disorders Diagnosis and Management Guidelines"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178111","article-title":"Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up","volume":"103","author":"Alter","year":"2018","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.50111","article-title":"Genotype and associated cancer risk in individuals with telomere biology disorders","volume":"7","author":"Niewisch","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-022-00662-8","article-title":"Clonal hematopoiesis and myeloid neoplasms in the context of telomere biology disorders","volume":"17","author":"Ferrer","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025023","article-title":"Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations","volume":"144","author":"Gutierrez-Rodrigues","year":"2024","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.03.211","article-title":"Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer","volume":"331","author":"Artandi","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200771","article-title":"Targeting the ribosome to treat multiple myeloma","volume":"32","author":"Maclachlan","year":"2024","journal-title":"Mol Therapy: Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415349","article-title":"Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B","volume":"120","author":"Rao","year":"2012","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.139","article-title":"Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"Wei","year":"2013","journal-title":"Oncogene"},{"key":"B118","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10549-011-1688-7","article-title":"Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer","volume":"133","author":"Moura","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B119","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.yexcr.2018.06.005","article-title":"Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity","volume":"370","author":"Bal\u00e7a-Silva","year":"2018","journal-title":"Exp Cell Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.8b12872","article-title":"Nucleolin is a functional binding protein for salinomycin in neuroblastoma stem cells","volume":"141","author":"Wang","year":"2019","journal-title":"J Am Chem Soc"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2019.08.032","article-title":"The association between lncRNA LINC01296 and the clinical characteristics in neuroblastoma","volume":"54","author":"Wang","year":"2019","journal-title":"J Pediatr Surg"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.02.007","article-title":"LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex","volume":"24","author":"Wang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/ph9040069","article-title":"Aptamer-mediated targeted delivery of therapeutics: an update","volume":"9","author":"Catuogno","year":"2016","journal-title":"Pharmaceuticals"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1217769","article-title":"Anti-nucleolin aptamer AS1411: an advancing therapeutic","volume":"10","author":"Van den Avont","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers","volume":"110","author":"Pourdehnad","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2281","article-title":"BET bromodomain inhibition of MYC-amplified medulloblastoma","volume":"20","author":"Bandopadhayay","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24678","article-title":"Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation of SESN2","volume":"9","author":"Lin","year":"2018","journal-title":"Oncotarget"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24618","article-title":"Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy","volume":"9","author":"Chaturvedi","year":"2018","journal-title":"Oncotarget"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0996","article-title":"A novel combination approach targeting an enhanced protein synthesis pathway in MYC-driven (Group 3) medulloblastoma","volume":"19","author":"Chaturvedi","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1186\/s12885-019-6291-z","article-title":"Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) medulloblastoma","volume":"19","author":"Chaturvedi","year":"2019","journal-title":"BMC Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac144","article-title":"Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression","volume":"4","author":"Wynn","year":"2022","journal-title":"Neuro-Oncol Adv"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171136","article-title":"Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models","volume":"134","author":"Rodriguez-Blanco","year":"2024","journal-title":"J Clin Invest"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/path.2784","article-title":"The role of mutant p53 in human cancer","volume":"223","author":"Goh","year":"2011","journal-title":"J Pathol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.21037\/atm-20-6047","article-title":"Comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms\u2019 tumor","volume":"8","author":"He","year":"2020","journal-title":"Ann Transl Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010098","article-title":"Antitumor effects of PRIMA-1 and PRIMA-1Met (APR246) in hematological Malignancies: still a mutant p53-dependent affair","volume":"10","author":"Menichini","year":"2021","journal-title":"Cells"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21070949","article-title":"Novel improved synthesis of HSP70 inhibitor, Pifithrin-\u03bc. In vitro synergy quantification of Pifithrin-\u03bc combined with Pt drugs in prostate and colorectal cancer cells","volume":"21","author":"McKeon","year":"2016","journal-title":"Molecules"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41598-020-58051-1","article-title":"Pifithrin-\u03b1 alters p53 post-translational modifications pattern and differentially inhibits p53 target genes","volume":"10","author":"Zhu","year":"2020","journal-title":"Sci Rep"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15840","article-title":"RITA displays anti-tumor activity in medulloblastomas independent of TP53 status","volume":"8","author":"Gottlieb","year":"2017","journal-title":"Oncotarget"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4093","article-title":"rRNA synthesis inhibitor, CX-5461, activates ATM\/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis","volume":"6","author":"Negi","year":"2015","journal-title":"Oncotarget"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5775","article-title":"Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility","volume":"6","author":"Brighenti","year":"2015","journal-title":"Oncotarget"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2362","article-title":"Molecular pathways: the eIF4F translation initiation complex\u2014new opportunities for cancer treatment","volume":"23","author":"Malka-Mahieu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.25","article-title":"Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A","volume":"3","author":"Cencic","year":"2013","journal-title":"Blood Cancer J"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-2","article-title":"Homoharringtonine and omacetaxine for myeloid hematological Malignancies","volume":"7","author":"L\u00fc","year":"2014","journal-title":"J Hematol Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-262808","article-title":"Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia","volume":"117","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1818539116","article-title":"Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-\u03baB repressing factor","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164933","article-title":"Venetoclax in combination with homoharringtonine and cytarabine in the treatment of relapsed\/refractory early T-cell precursor acute lymphoblastic leukaemia: A single arm, multicenter, prospective, phase II, pilot trial","volume":"140","author":"Yu","year":"2022","journal-title":"Blood"},{"key":"B148","unstructured":"Efficacy analysis of comparison of CAMS (Chinese academy of medical sciences)?\u20142005 trial and CAMS-2009 trial for pediatric acute myeloid leukemia"},{"key":"B149","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/s41467-022-31199-2","article-title":"Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies","volume":"13","author":"Hilton","year":"2022","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12967-025-06473-8","article-title":"The G-quadruplex ligand CX-5461: an innovative candidate for disease treatment","volume":"23","author":"Li","year":"2025","journal-title":"J Transl Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.30.25336525","article-title":"Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells","author":"Kanwal","year":"2025"},{"key":"B152","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1200\/jco.2006.24.18_suppl.3082","article-title":"Phase I clinical trial of CX-3543, a pro-apoptotic antitumor agent","volume":"24","author":"Marschke","year":"2006","journal-title":"J Clin Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283099","article-title":"A novel approach to overcome drug resistance in acute myeloid leukemia","volume":"108","author":"Mazewski","year":"2023","journal-title":"Haematologica"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282791","article-title":"Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory\/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine","volume":"108","author":"Assouline","year":"2023","journal-title":"Haematologica"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30199","article-title":"Modulation of tumor eIF4E by antisense inhibition: A phase I\/II translational clinical trial of ISIS 183750\u2014an antisense oligonucleotide against eIF4E\u2014in combination with irinotecan in solid tumors and irinotecan\u2010refractory colorectal cancer","volume":"139","author":"Duffy","year":"2016","journal-title":"Int J Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2424286122","article-title":"eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer","volume":"122","author":"Boyer","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14432","article-title":"CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours","volume":"8","author":"Xu","year":"2017","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1200\/JCO.2020.38.15_suppl.3112","article-title":"A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment","volume":"38","author":"El-Khoueiry","year":"2020","journal-title":"J Clin Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2021.06.005","article-title":"PD-L1 regulation revisited: impact on immunotherapeutic strategies","volume":"27","author":"Lucibello","year":"2021","journal-title":"Trends Mol Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.845","article-title":"A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia","volume":"5","author":"Reed","year":"2016","journal-title":"Cancer Med"},{"key":"B161","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/OTT.S41786","article-title":"Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia","volume":"7","author":"Li","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111245","article-title":"A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E","volume":"100","author":"Assouline","year":"2015","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:30:54Z","timestamp":1781843454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":162,"alternative-id":["10.3389\/fonc.2026.1832877"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1832877","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1832877"}}